<font color="#000000"><font size="4"><font face="verdana,sans-serif">Dear Gerlind,</font></font></font><div><font color="#000000"><font size="4"><font face="verdana,sans-serif"><br></font></font></font></div><div><font color="#000000"><font size="4"><font face="verdana,sans-serif">I took a very fast look in PubMed in respect to the use of Rifampicin in CL. Data shows an apparent advantage, but not something to be used alone. But in a desperate situation it may be worthy to try.</font></font></font></div>
<div><font color="#000000"><font size="4"><font face="verdana,sans-serif"><br></font></font></font></div><div><font color="#000000"><font size="4"><font face="verdana,sans-serif">One of your comment specially called my attention: the prolonged use of miltefosine in VL HIV patients. If so, they had not developed resistance, which is quite different from DCL. Again, is parasite playing a role? Does L. amazonensis has a peculiar system to develop drug resistance?</font></font></font></div>
<div><font color="#000000"><font size="4"><font face="verdana,sans-serif"><br></font></font></font></div><div><font color="#000000"><font size="4"><font face="verdana,sans-serif">Although treatment with miltefosine would lead to resistance, it is worthy to try and see if new lesions do not develop in such a severity.</font></font></font></div>
<div><font color="#000000"><font size="4"><font face="verdana,sans-serif"><br></font></font></font></div><div><font color="#000000"><font size="4"><font face="verdana,sans-serif">Kind regards,</font></font></font></div><div>
<font color="#000000"><font size="4"><font face="verdana,sans-serif"><br></font></font></font></div><div><font color="#000000"><font size="4"><font face="verdana,sans-serif">Carlos. <br></font></font></font><br><div class="gmail_quote">
2011/7/12 Gerlind Anders <span dir="ltr"><<a href="mailto:Gerlind.Anders@gmx.net">Gerlind.Anders@gmx.net</a>></span><br><blockquote class="gmail_quote" style="margin:0 0 0 .8ex;border-left:1px #ccc solid;padding-left:1ex;">
<br>
Dea All,<br>
<br>